SMAD4 Gene: Structure, Function, and Clinical Significance

A comprehensive overview of the SMAD4 gene, its protein product, associated diseases, expression patterns, and mutations.

Gene Information Card

Symbol SMAD4
Full Name SMAD family member 4
Gene Type Protein coding
Chromosomal Location 18q21.2
NCBI Gene ID 4089 ncbi.nlm.nih.gov/gene/4089
Ensembl ID ENSG00000141646
UniProt ID Q13485
OMIM ID 600993
HGNC ID 6770
Aliases DPC4, MADH4, MYHRS

Description

The SMAD4 gene encodes a critical intracellular mediator of the transforming growth factor-beta (TGF-beta) signaling pathway. SMAD4 forms complexes with receptor-regulated SMADs (R-SMADs) and translocates to the nucleus to regulate gene transcription. It acts as a tumor suppressor, and its loss or mutation is implicated in various cancers and developmental disorders.

Disease Associations

Disease category Pathophysiological mechanism Genomic evidence
Juvenile polyposis syndrome Germline mutations in SMAD4 lead to haploinsufficiency or dominant-negative effects, disrupting TGF-beta signaling and promoting intestinal polyp formation. OMIM #174900; ClinVar
Pancreatic cancer Somatic loss or mutation of SMAD4 (often homozygous deletion) inactivates TGF-beta tumor suppressor activity, contributing to tumor progression and metastasis. COSMIC; ClinVar
Colorectal cancer SMAD4 mutations or loss of heterozygosity at 18q21 are frequent, impairing TGF-beta-mediated growth inhibition and promoting tumor invasion. COSMIC; ClinVar
Myhre syndrome Specific missense mutations in SMAD4 (e.g., p.Ile500Val, p.Arg496Cys) cause gain-of-function or dominant-negative effects, leading to connective tissue and skeletal abnormalities. OMIM #139210; ClinVar
Hereditary hemorrhagic telangiectasia Some SMAD4 mutations cause combined juvenile polyposis and hereditary hemorrhagic telangiectasia, affecting vascular development. OMIM #175050; ClinVar

Expression Profile

Tissue Expression
Tissue nTPM level
Pancreas High High
Small intestine High High
Colon High High
Stomach High High
Liver Medium Medium
Lung Medium Medium
Kidney Medium Medium
Brain Low Low
Heart Low Low
Skeletal muscle Low Low
Cell Line Expression
Cell Line nTPM Notes
HeLa (cervical cancer) High Ubiquitous expression; used in TGF-beta studies
A549 (lung cancer) Medium SMAD4 expression present; responsive to TGF-beta
MCF7 (breast cancer) Medium Expression varies; involved in estrogen/TGF-beta crosstalk
HCT116 (colorectal cancer) High Wild-type SMAD4; used in SMAD4 functional assays
PANC-1 (pancreatic cancer) Low Reduced SMAD4 expression; reflects pancreatic cancer phenotype
Data source:Human Protein Atlas(proteinatlas.org)

Mutations & Variants

Hotspot Mutations
Variant Type Frequency Functional Description
c.1244_1245delAG (p.Glu415Valfs*3) Frameshift Rare Loss of function; truncates protein, impairing SMAD complex formation
c.1082G>A (p.Arg361His) Missense Rare Dominant-negative; disrupts DNA binding and transcriptional activity
c.1498A>G (p.Ile500Val) Missense Rare Gain-of-function; associated with Myhre syndrome
c.1486C>T (p.Arg496Cys) Missense Rare Gain-of-function; associated with Myhre syndrome
Whole gene deletion Copy number loss Common in pancreatic cancer Loss of function; complete loss of SMAD4 protein
Mutation functional classification

Loss of Function (LOF)

Most SMAD4 mutations in cancer are loss-of-function, including frameshift, nonsense, and homozygous deletions, leading to reduced or absent protein and impaired TGF-beta signaling.

Gain of Function (GOF)

Specific missense mutations (e.g., p.Ile500Val, p.Arg496Cys) in Myhre syndrome result in gain-of-function, enhancing SMAD4 transcriptional activity and causing abnormal TGF-beta responses.

Dominant Negative (DN)

Some missense mutations (e.g., p.Arg361His) act as dominant-negative, interfering with wild-type SMAD4 function by forming non-functional complexes with R-SMADs.

Gene Ontology (GO)

• DNA binding • Transcription factor activity
• Protein binding • Signal transducer activity
• TGF-beta receptor signaling pathway • Regulation of transcription by RNA polymerase II
• Cell cycle arrest • Apoptotic process
• Epithelial to mesenchymal transition • SMAD protein complex

Pathways

• TGF-beta signaling pathway
• Activin signaling pathway
• BMP signaling pathway
• Regulation of epithelial to mesenchymal transition
• Colorectal cancer pathway
• Pancreatic cancer pathway

Protein Summary

SMAD4 is a 552-amino acid protein with two conserved domains: MH1 (MAD homology 1) and MH2 (MAD homology 2), connected by a linker region. The MH1 domain mediates DNA binding, while the MH2 domain is involved in protein-protein interactions and transcriptional activation. SMAD4 acts as a common mediator SMAD (co-SMAD) that partners with receptor-regulated SMADs (SMAD1/2/3/5/8) to transduce TGF-beta family signals. It shuttles between cytoplasm and nucleus, and its activity is regulated by phosphorylation, ubiquitination, and interaction with various cofactors. Loss of SMAD4 function is a hallmark of several cancers, while gain-of-function mutations cause developmental syndromes.

Related Products

Product name Cat.No. Species Gene ID
SMAD4 Knockout HTR-8/SVneo Cell Line EDJ-KZ479 Human 4089 Details Get a Quote
SMAD4 Knockout HeLa Cell Line EDJ-KQ18642 Human 4089 Details Get a Quote
SMAD4 Knockout HCT 116 Cell Line EDJ-KQ18641 Human 4089 Details Get a Quote
SMAD4 Knockout A-549 Cell Line EDJ-KQ18640 Human 4089 Details Get a Quote
SMAD4 Knockout HEK293 Cell Line EDJ-KQ401 Human 4089 Details Get a Quote

Biological Process

Gene Expression and Regulation: A Complete Technical Map from Mechanism to Validated Cell Models

Promoters, Enhancers and 3D Genome Organization: How to Validate Regulatory Relationships with Editing and Interference Tools

Enhancer–Gene Pair Validation: A Complete Technical Roadmap from Candidate Element to Publishable Evidence

CRISPR Deletion vs CRISPRi for Regulatory Elements: Choosing by Evidence Requirement

Building Reporter Cell Lines for Quantitative Regulatory Readouts

TAD Boundaries and Insulators: What They Constrain and What They Do Not Prove

Super-Enhancers and Cell Identity: Design Strategies for Functional Validation

Validating Transcription Factor Binding Sites: From ChIP Peaks to Functional Evidence

From GWAS Signal to Causal Variant: Functional Validation of Non-Coding Risk Loci

Enhancer Redundancy and Shadow Enhancers: Designing Controls That Catch Compensation

Core Promoter Elements: Dissecting Initiator, TATA and CpG-Island Promoters

Single-Cell Multi-Omics for Mapping Regulatory Elements in Heterogeneous Tissues

How Many Candidate Enhancers Can a Single CRISPRi Screen Test?

What Fragment Size Should Be Deleted When Removing an Enhancer?

How to Design sgRNAs for Enhancer Deletion

What Effect Size Counts as Biologically Meaningful in Enhancer Studies?

What Controls Are Required for a Regulatory Element Knockout?

How to Confirm a TAD Boundary Is Functional

Can ATAC-seq Alone Identify Functional Enhancers?

What Is a Shadow Enhancer, and Why Does It Break Your Screen?

How to Report Negative Results in Regulatory Element Studies

Distance Window or TAD Boundary: Which Constraint Matters More?

DNA Methylation, Histone Marks and Chromatin State: Selecting and Validating Epigenome-Editing Tools

CRISPRoff, dCas9-TET and dCas9-p300: A Practical Comparison for Targeted Epigenetic Editing

How Long Does Epigenetic Silencing Last? Stability, Inheritance and Reversibility

DNMT and TET Knockout Cell Lines: What Phenotypes to Expect and How to Verify Them

Reading Chromatin Accessibility: From ATAC-seq Peaks to Functional Hypotheses

Histone Modification Writers, Readers and Erasers: A Knockout Map

Assessing Off-Target Effects in Epigenetic Editing

Single-Cell Epigenomics: scATAC-seq and scChIP-seq in Development and Disease

Spatial Epigenomics: Mapping Modifications In Situ

Epigenetic Clocks and cfDNA Methylation as Biomarkers

Imprinting and Parent-of-Origin Expression: Why Allele-Specific Regulation Matters

What Is CRISPRoff and How Does It Differ From dCas9-KRAB?

How Stable Is Epigenetic Silencing Across Cell Divisions?

Which Cell Line Is Best for Studying DNA Methylation?

How to Validate a DNMT1 Knockout Clone

What Is a Differentially Methylated Region (DMR)?

Do Epigenetic Edits Create Off-Target Methylation Changes?

How to Link ATAC-seq Changes to Gene Expression Causality

What Is Histone Lactylation and Why Does It Matter?

How to Design a Single-Cell ATAC-seq Experiment

Can Epigenetic Editing Restore a Silenced Gene?

lncRNA, miRNA and RNA Modification: A Complete Path from Function Prediction to Phenotype Validation

Why lncRNA Knockouts Often Show No Phenotype — and How to Design Around It

lncRNA Functional Validation: Knockout vs Knockdown vs Antisense Oligonucleotides

m6A Writers, Readers and Erasers: Mapping and Testing RNA Modification Function

miRNA–Target Validation: Evidence Beyond Luciferase Reporter Assays

RNA-Binding Protein Screens: Design, Readouts and Hit Prioritization

Alternative Splicing Regulation: Isoform-Level Validation Strategies

Circular RNA Biology: Detection, Function and Experimental Pitfalls

RNA Localization and the Spatial Regulation of Translation

Why Does an lncRNA Knockout Often Show No Phenotype?

Knockdown vs Knockout for lncRNA: Which Is More Informative?

How Long a Fragment Should Be Deleted for an lncRNA Knockout?

Which m6A Antibody Should I Use for MeRIP-seq?

What Is the Difference Between RIP-seq and CLIP-seq?

How to Validate a miRNA Target Without a Luciferase Assay

How Many Isoforms Must an Alternative Splicing Study Cover?

Is Circular RNA Detection Reliable Across Platforms?

How to Verify RNA Localization Experimentally

What Proportion of Annotated lncRNAs Are Functional?

CRISPR Knockout, Knock-In, Activation and Screening: A Strategy Matrix for Regulatory Research

Knockout, CRISPRi or Base Editing? A Six-Dimension Decision Matrix

Genome-Wide CRISPR Screening: Library Coverage, MOI and Readout Design

Perturb-seq and Single-Cell Screens: Linking Perturbation to Transcriptional Programs

Essential Genes and Lethal Phenotypes: How to Study What You Cannot Knock Out

Base Editing and Prime Editing in Regulatory Research: When Precision Beats Deletion

Quantifying Editing Efficiency and Off-Target Events: A Practical Framework

Choosing a Cas9 Variant and Delivery Format for Your Cell Type

Multiplex Editing and Temporal Control of Gene Regulation

How Much Library Coverage Is Enough for a Genome-Wide Screen?

What MOI Should I Use for a Lentiviral CRISPR Library?

How to Screen a Non-Proliferative Phenotype

How to Study an Essential Gene with CRISPR

What Is the Difference Between Base Editing and Prime Editing?

How to Measure Knockout Efficiency in a Cell Pool

How to Design a Multiplex Knockout Experiment

Which Cas9 Variant Works Best for AAV Delivery?

What Is a Safe-Harbor Locus for Knock-In?

How Many Clones Must Be Screened to Confirm a Homozygous Knockout?

From Pathway to Model: Validation Paradigms in Cancer, Neuro, Immune and Metabolic Research

Oncogene Dependency and Synthetic Lethality: Building the Right Validation Model

Enhancer Dysregulation in Neurodegeneration: Lessons from Glial and Neuronal Models

CAR-T and ADCC Target Validation: Engineering Immune Cell Lines for Functional Assays

Hippo, WNT and PI3K: Validating Pathway Nodes with Knockout Cell Lines

Drug Target Validation: A Standardized Workflow from Hit to Model

Metabolic Pathway Enzymes: Building Loss-of-Function Models

Gene Editing in iPSC and Organoids: Constraints, Timelines and Readouts

Disease-Associated Non-Coding Variants: From Risk Locus to Cellular Phenotype

How to Validate Pathway Activation After a Knockout

How Long Does iPSC Gene Editing Take?

How to Edit Organoids Without Disrupting Their Structure

Which Cell Line Models ADCC Most Reliably?

How to Build a Synthetic Lethality Screen

What Is a Good Model for Enhancer Dysregulation in Neurons?

How to Validate a Drug Target Before Committing to a Programme

Why Does My Knockout Cell Line Lose the Phenotype After Passaging?

How to Choose Between Human and Mouse Cell Models

What QC Documentation Should Accompany a Custom Cell Line?

Gene Knockout Feasibility Self-Assessment: Ten Constraints That Decide the Project

Pathway-to-Model Reference Chart: Key Genes × Recommended Cell Models

Working with Hard-to-Transfect Cells: A Delivery Strategy Guide

How We Validate Knockout Clones: PCR, Sanger and Western Blot in Combination

Custom Knockout Cell Line Service: Strategy Design, Single-Cell Cloning and Triple Validation

Stable dCas9-KRAB and Cas9 Expression Cell Lines

Knock-In Reporter Cell Lines for Regulatory Readouts

Genome-Wide CRISPR Library Screening Service

Services Comparison: In-House vs CRO vs Off-the-Shelf Cell Lines

Epigenetic Editing Enters the Clinic: What It Means for Research Models

AI Sequence Models in Regulatory Genomics: Hype, Reality and Where They Help

Live-Cell Imaging Rewrites the Rules of Transcriptional Regulation

Spatial and Single-Cell Multi-Omics: The Next Validation Frontier

From CRISPR Screens to Programmable Medicine: A Five-Year Outlook

Contact Us
*
*
*
How did you hear about us: